ICH Is the Bridge to EU GMP
EU GMP is the destination; ICH is the road. EudraLex Volume 4 adopts the ICH guidelines wholesale — build to ICH once and you build to the bar every European market enforces.
Read the pieceEU GMP
EU GMP — the European Union’s manufacturing standard, published as EudraLex Volume 4 — is where cannabis, pharmaceutical, and equipment manufacturers have to arrive to sell into Europe. We help you get there: gap assessment, remediation, integrated quality systems, and the export-readiness work that closes the gap between where you are and what a European inspector expects.
State-licensed cultivators and manufacturers building to EU GACP + GMP for export — the gap assessment, the Qualified Person path, and the remediation roadmap.
Finished-product and active-substance manufacturers building one quality system to the highest common bar across EU GMP, FDA, and ICH.
Turning an operations manual into a GMP-aligned equipment documentation package customers can use for IQ/OQ qualification.
Long-form, practitioner-written pieces that map the whole terrain — from the standard itself to qualifying a single machine.
EU GMP is the destination; ICH is the road. EudraLex Volume 4 adopts the ICH guidelines wholesale — build to ICH once and you build to the bar every European market enforces.
Read the pieceThe two frameworks overlap 70–80%. Export programs fail in the 20% that diverges: the Qualified Person, the annex system, contamination control, and the distinct EU GDP regime. A clause-level comparison.
Read the pieceFor equipment manufacturers: the qualification lifecycle (URS → DQ → FAT/SAT → IQ → OQ → PQ per Annex 15), the documentation package an OEM must ship, and why 'CE marked' is not 'GMP-ready.'
Read the pieceDon't build a separate quality system for each market. Build one integrated system to ICH Q10 / EU-GMP / 21 CFR 211 at the highest common bar — sequential builds cost ~2.2× the integrated approach.
Read the pieceEU GMP (Good Manufacturing Practice) is the European Union's framework for manufacturing medicinal products and active substances, published as EudraLex Volume 4. It is principle-based and elaborated through a system of annexes, and it requires a Pharmaceutical Quality System (ICH Q10), risk management (ICH Q9), and certification of every batch by a Qualified Person before release.
EU GMP (EudraLex Volume 4) and FDA GMP (21 CFR Parts 210 and 211) agree on roughly 70–80% of substance. The expensive differences are structural: the EU requires a named Qualified Person to certify every batch, an explicit ICH Q10 quality system, a numbered annex system, a Site Master File, and a distinct Good Distribution Practice regime. Export programs fail in that diverging 20%, not the overlap.
The EU is a founding regulatory member of ICH, and EudraLex Volume 4 adopts ICH guidelines at its load-bearing points — Part II is ICH Q7, the required quality system is ICH Q10, and risk management is ICH Q9. Building a quality system, stability program, and analytical methods to ICH therefore builds to the structural core of EU GMP, once, for every European market.
Manufacturing for the EU medicinal market requires compliance with EU GMP and, for finished products, certification of each batch by a Qualified Person. Intrepid gets an operation ready to meet that bar — gap assessment, remediation, and quality-system build — but readiness is not the grant: national competent authorities and the Qualified Person make the compliance and release decisions.
An EU GMP gap assessment maps a cultivation and manufacturing operation against EudraLex Volume 4 (Parts I and II) and the relevant annexes, identifies the deltas that gate export — the Qualified Person, Annex 1 contamination control, the Site Master File, Annex 15 validation, EU GDP — and delivers a prioritized, sequenced remediation roadmap. It is the scoped Stage 1 that defines the rest of the work.
Equipment is never 'GMP compliant' on its own — GMP is a property of an operation, not a machine. Equipment can be made qualifiable: designed to GMP engineering principles and shipped with the controlled documentation a regulated buyer needs to qualify it (DQ, IQ, OQ, PQ) under Annex 15. CE/PED/ATEX conformity marking is a separate question from GMP qualification.
It depends on the starting state and scope, which is exactly what a Stage 1 gap assessment determines. Realistic programs are phased and decision-gated: a scoping and gap assessment first, then remediation and quality-system build, with the Qualified Person timeline typically on the critical path for export.
Tell us where you are. The most useful first move is usually a short note describing the operation — we’ll tell you honestly what EU GMP readiness takes from here.